<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8" />
<title>Commure Opportunity Analysis - KF Sell</title>
<meta name="viewport" content="width=device-width,initial-scale=1" />
<style>
* { box-sizing: border-box; }
body {
font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Arial, sans-serif;
line-height: 1.6;
color: #2c3e50;
max-width: 1200px;
margin: 0 auto;
padding: 20px;
background: linear-gradient(135deg, #f5f7fa 0%, #e8eef5 100%);
}
h1 {
color: #2c3e50;
border-bottom: 4px solid #3498db;
padding-bottom: 15px;
margin-top: 0;
font-size: 2.2em;
font-weight: 700;
}
h2 {
color: #34495e;
margin-top: 30px;
font-size: 1.5em;
font-weight: 600;
}
.summary, .metrics, .toc {
background: #fff;
padding: 25px;
border-radius: 12px;
margin-bottom: 25px;
box-shadow: 0 4px 6px rgba(0,0,0,0.07);
border: 1px solid rgba(0,0,0,0.05);
}
.metrics-grid {
display: grid;
grid-template-columns: repeat(auto-fit, minmax(240px, 1fr));
gap: 20px;
margin-top: 15px;
}
.metric-box {
background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
padding: 20px;
border-radius: 10px;
color: white;
box-shadow: 0 4px 6px rgba(102, 126, 234, 0.3);
transition: transform 0.2s;
}
.metric-box:hover {
transform: translateY(-2px);
box-shadow: 0 6px 12px rgba(102, 126, 234, 0.4);
}
.metric-box:nth-child(4) {
box-shadow: 0 4px 6px rgba(245, 87, 108, 0.3);
}
.metric-box:nth-child(4):hover {
box-shadow: 0 6px 12px rgba(245, 87, 108, 0.4);
}
.metric-label {
font-size: 0.9em;
opacity: 0.9;
margin-bottom: 8px;
font-weight: 500;
}
.metric-value {
font-size: 2em;
font-weight: bold;
}
.toc ul {
columns: 2;
column-gap: 30px;
margin: 0;
padding-left: 0;
list-style: none;
}
.toc li {
margin-bottom: 12px;
break-inside: avoid;
padding: 8px 12px;
border-radius: 6px;
transition: background 0.2s;
}
.toc li:hover {
background: #f8f9fa;
}
.toc a {
color: #2c3e50;
text-decoration: none;
display: flex;
justify-content: space-between;
align-items: center;
gap: 10px;
}
.toc a:hover {
color: #3498db;
}
.acv-badge {
background: #3498db;
color: white;
padding: 2px 10px;
border-radius: 12px;
font-size: 0.85em;
font-weight: 600;
white-space: nowrap;
}
table {
background: #fff;
box-shadow: 0 4px 6px rgba(0,0,0,0.07);
border-radius: 12px;
overflow: hidden;
border-collapse: collapse;
width: 100%;
margin-bottom: 30px;
border: 1px solid rgba(0,0,0,0.05);
}
td {
border-bottom: 1px solid #e8eef5;
padding: 14px 16px;
vertical-align: top;
}
tr:last-child td {
border-bottom: none;
}
.th {
background: #f8f9fa;
font-weight: 600;
width: 28%;
color: #495057;
font-size: 0.95em;
}
.head {
background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
color: #fff;
font-weight: 600;
padding: 16px;
font-size: 1.1em;
text-align: center;
}
ul {
margin: 0;
padding-left: 20px;
}
ul li {
margin-bottom: 6px;
}
.badge {
padding: 4px 12px;
border-radius: 12px;
font-size: 0.8em;
font-weight: 600;
display: inline-block;
}
.badge-urgent {
background: #dc3545;
color: white;
animation: pulse 2s infinite;
}
.badge-high {
background: #ffc107;
color: #333;
}
.badge-commit {
background: #28a745;
color: white;
}
.badge-attention {
background: #17a2b8;
color: white;
}
@keyframes pulse {
0%, 100% { opacity: 1; }
50% { opacity: 0.7; }
}
.summary p {
margin: 8px 0;
font-size: 1.05em;
}
.metrics p {
margin: 12px 0;
line-height: 1.8;
}
@media (max-width: 768px) {
.toc ul {
columns: 1;
}
.metrics-grid {
grid-template-columns: 1fr;
}
}
@media print {
body {
background: #fff;
}
.toc {
page-break-after: always;
}
.metric-box {
box-shadow: none;
border: 2px solid #667eea;
}
}
</style>
</head>
<body>
<h1>Commure Opportunity Analysis - KF Sell</h1>

<div class="summary">
<p><strong>Report Generated:</strong> Friday, October 3, 2025 at 8:16:38 PM</p>
<p><strong>Total Opportunities Analyzed:</strong> 35</p>
</div>

<div class="metrics">
<h2>Executive Summary</h2>
<div class="metrics-grid">
<div class="metric-box">
<div class="metric-label">Total Pipeline Value</div>
<div class="metric-value">$26,294,604</div>
</div>
<div class="metric-box">
<div class="metric-label">Average KF Score</div>
<div class="metric-value">63</div>
</div>
<div class="metric-box">
<div class="metric-label">Total Opportunities</div>
<div class="metric-value">35</div>
</div>
<div class="metric-box" style="background: linear-gradient(135deg, #f093fb 0%, #f5576c 100%);">
<div class="metric-label">Commit Value</div>
<div class="metric-value">$6,967,548</div>
</div>
</div>
<div style="margin-top:25px; padding-top:20px; border-top:2px solid #e8eef5;">
<p><strong>Stage Distribution:</strong> 4. Proposal/Price Quote: 10 | 3. Scoping: 8 | 5. Negotiate/Contract Sent: 7 | 7. Final Contract Execution: 5 | 1. Qualifying: 3 | 6. Contract Red-Line Received: 2</p>
<p><strong>Forecast Categories:</strong> Best Case: 20 | Commit: 6 | N/A: 6 | Omitted: 3</p>
</div>
</div>

<div class="toc">
<h2>Table of Contents</h2>
<p style="color:#6c757d;font-size:0.95em;margin-bottom:15px;">Opportunities sorted by ACV (highest to lowest)</p>
<ul><li><a href="#opp-0">Hughston Clinic - PKScribe/RCM<span class="acv-badge">$5,280,000</span></a></li><li><a href="#opp-1">Compassus - Full Cycle RCM<span class="acv-badge">$4,000,000</span></a></li><li><a href="#opp-2">Nathan Littauer Hospital - RCM - New Business<span class="acv-badge">$3,000,000</span></a></li><li><a href="#opp-3">Allegiance Healthcare<span class="acv-badge">$2,000,000</span></a></li><li><a href="#opp-4">LIfepoint - Enterprise Scribe (Meditech starting location)<span class="acv-badge">$2,000,000</span></a></li><li><a href="#opp-5">Valley Health - PKScribe<span class="acv-badge">$1,200,000</span></a></li><li><a href="#opp-6">Baystate - PK Autonomous Coding co-dev<span class="acv-badge">$1,000,000</span></a></li><li><a href="#opp-7">OBHG RCM replacement<span class="acv-badge">$1,000,000</span></a></li><li><a href="#opp-8">USC Keck Autonomous Coding<span class="acv-badge">$1,000,000</span></a></li><li><a href="#opp-9">SUNY Upstate Medical University - Strongline - Duress - New Business<span class="acv-badge">$850,000</span></a></li><li><a href="#opp-10">HCA Home Health &amp; Hospice - Scribe - Existing Business<span class="acv-badge">$750,000</span></a></li><li><a href="#opp-11">St. Bernards- Scribe/Agents<span class="acv-badge">$750,000</span></a></li><li><a href="#opp-12">CUC - Platform Sale<span class="acv-badge">$500,000</span></a></li><li><a href="#opp-13">Doctors RCM<span class="acv-badge">$500,000</span></a></li><li><a href="#opp-14">UHS - Referral<span class="acv-badge">$500,000</span></a></li><li><a href="#opp-15">Sutter-Caring Contacts<span class="acv-badge">$345,000</span></a></li><li><a href="#opp-16">Optum Wellmed new instance of PK<span class="acv-badge">$318,000</span></a></li><li><a href="#opp-17">Chapters- Intake<span class="acv-badge">$260,000</span></a></li><li><a href="#opp-18">LHS-RCM<span class="acv-badge">$250,000</span></a></li><li><a href="#opp-19">Doctors Scribe<span class="acv-badge">$200,000</span></a></li><li><a href="#opp-20">Baxter Regional Medical Center - Strongline - New Business<span class="acv-badge">$134,200</span></a></li><li><a href="#opp-21">SUNY expansion practices<span class="acv-badge">$117,656</span></a></li><li><a href="#opp-22">CA DSH - Athelas Home Hardware &amp; Service - New Business<span class="acv-badge">$93,123</span></a></li><li><a href="#opp-23">Portneuf Medical Center - Strongline - Duress - New Business<span class="acv-badge">$76,425</span></a></li><li><a href="#opp-24">HCA UK - Integrations Project<span class="acv-badge">$69,200</span></a></li><li><a href="#opp-25">Shore Medical Center - Strongline - New Business<span class="acv-badge">$65,000</span></a></li><li><a href="#opp-26">Beth Israel Bayridge - Duress - Expansion<span class="acv-badge">$20,000</span></a></li><li><a href="#opp-27">Beth Israel Anna Jaques - Strongline - Expansion<span class="acv-badge">$16,000</span></a></li><li><a href="#opp-28">Boston Childrens - Strongline Asset Tracking<span class="acv-badge">$0</span></a></li><li><a href="#opp-29">CAO + Medvanta RCM + Enterprise Bundle<span class="acv-badge">$0</span></a></li><li><a href="#opp-30">Chesapeake Regional MC - Pilot conversion<span class="acv-badge">$0</span></a></li><li><a href="#opp-31">Firelands Regional Med Center - Ambient ENT<span class="acv-badge">$0</span></a></li><li><a href="#opp-32">KPC Group (AKA KPC Healthcare) - Pilot Conversion<span class="acv-badge">$0</span></a></li><li><a href="#opp-33">SIU Med CC + Analytics<span class="acv-badge">$0</span></a></li><li><a href="#opp-34">South County Hospital - PK + Ambient<span class="acv-badge">$0</span></a></li></ul>
</div>

<h2>Detailed Opportunity Analysis</h2>

<table id="opp-0">
<tr><td class="head" colspan="2">Opportunity #1</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>Hughston Clinic - PKScribe/RCM</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Mick Majewski</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>5. Negotiate/Contract Sent</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Commit</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$5,280,000</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>9/30/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#ffc107;">73</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>High-value opportunity at $5,280,000 with a close date of 9/30/25. The deal is in 'Negotiate/Contract Sent' with a Commit forecast, indicating strong intent but not yet signed. There are no manager notes or bluesheet data available to illuminate risk, and no red flags are recorded. The principal risk is potential delays in contract finalization or procurement approvals, which could push the close date or reduce likelihood of conversion. The absence of explicit next steps or blue sheet insights means governance should be tightened with a 1â€“2 week action plan to confirm terms and executive sign-off.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Potential delays in contract execution and approvals (legal, procurement, or IT onboarding) that could push the close date and threaten the commit forecast.</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Align with legal and an executive sponsor to accelerate review; lock in a signed term sheet/contract by the next milestone; establish a shared milestones calendar and weekly check-ins.</span></td>
</tr>
</table>

<table id="opp-1">
<tr><td class="head" colspan="2">Opportunity #2</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>Compassus - Full Cycle RCM</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Eric Valentin</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>4. Proposal/Price Quote</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Best Case</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$4,000,000</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>10/31/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#28a745;">97</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>KF score of 97 indicates strong alignment with buying criteria and a high win probability based on current data. The lack of Manager Notes and Bluesheet data creates visibility gaps around customer urgency, champion, and potential blockers. The opportunity is in Proposal/Price Quote with a Best Case forecast and a sizable $4,000,000 ACV, which suggests significant impact if closed. The close date of 10/31/25 provides a near-term timeline that will require disciplined execution of next steps and stakeholder alignment. To improve closure probability, ensure explicit next steps, pricing terms, and anticipated procurement steps are documented with the customer.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Ambiguity in next steps and stakeholder alignment could stall progress</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Capture explicit next steps with the owner and schedule a checkpoint with the customer to lock milestones</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>Schedule a price/solution alignment call with stakeholders (Proposed)</li><li>Confirm decision-making timeline and assign owners to drive to the next stage (Proposed)</li></ul></td>
</tr>
</table>

<table id="opp-2">
<tr><td class="head" colspan="2">Opportunity #3</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>Nathan Littauer Hospital - RCM - New Business</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Eric Valentin</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>4. Proposal/Price Quote</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Best Case</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$3,000,000</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>10/31/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#ffc107;">67</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td> Nathan Littauer Hospital opportunity is a high-value new business with an ACV of $3,000,000 and is currently in the 4. Proposal/Price Quote stage with a Best Case forecast. There are no manager notes or Bluesheet data available to illuminate customer constraints, risks, or procurement expectations. No red flags are documented in the data. The lack of Next Steps in the record creates ambiguity around the path to closing. The key risk is timing and alignment with the hospital's procurement cycle; ensuring clear milestones and decision criteria will help improve the probability from Best Case toward a Commit.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">No explicit risks documented in provided fields</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Request Manager Notes or Bluesheet updates to surface risks and identify critical milestones; align on decision criteria and procurement requirements.</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>(Proposed) Schedule a discovery call with the client to confirm timeline and decision milestones.</li><li>(Proposed) Request updated Bluesheet/Manager Notes to surface risks and dependencies.</li></ul></td>
</tr>
</table>

<table id="opp-3">
<tr><td class="head" colspan="2">Opportunity #4</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>Allegiance Healthcare</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Mick Majewski</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>3. Scoping</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Best Case</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$2,000,000</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>10/31/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#ffc107;">75</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>Allegiance Healthcare is currently in the Scoping stage with a Best Case forecast and a potential ACV of $2,000,000. There is no Manager Forecast Notes or Bluesheet data documented, which indicates limited formal guidance or customer-context at this time. The absence of a defined Next Step or concrete scope increases the risk that requirements and sponsor alignment could shift, slowing progression to a formal proposal. Although the KF score of 75 signals favorable momentum, a proactive discovery session is needed to lock in scope, timeline, and decision rights. Success hinges on securing a sponsor, clarifying the scope, and establishing a firm scoping plan with clear ownership and milestones.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Ambiguity in scope and sponsor engagement could delay progress.</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Schedule a dedicated scoping session with the customerâ€™s sponsor and decision-makers; document the defined scope, success criteria, and a realistic timeline to move toward a formal proposal.</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>Schedule scoping call with customer to confirm requirements</li><li>Prepare and share scoping proposal and timeline (Proposed)</li><li>Identify and confirm sponsor/decider within customer and align internal teams (Proposed)</li></ul></td>
</tr>
</table>

<table id="opp-4">
<tr><td class="head" colspan="2">Opportunity #5</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>LIfepoint - Enterprise Scribe (Meditech starting location)</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Dane Axelgard</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>4. Proposal/Price Quote</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Best Case</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$2,000,000</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>10/15/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#ffc107;">67</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>Enterprise Scribe opportunity at $2,000,000 in a Proposal/Price Quote stage with Best Case forecast and a 10/15/25 close. The large value aligns with strategic projects, and there is an established price quote indicating momentum. There are no manager notes or bluesheet data available to surface blockers, and no red flags have been logged. The top risk centers on timing and stakeholder alignment; with a 10/15 deadline, any procurement delays or competing priorities could derail the close. To mitigate, formalize a decision governance plan, confirm executive sponsorship, and secure procurement/IT approvals by early next week.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Timing and stakeholder alignment risk could derail the close if procurement or decision makers delay.</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Formalize a decision governance plan, secure executive sponsorship, and obtain procurement/IT approvals by an accelerated deadline.</span></td>
</tr>
</table>

<table id="opp-5">
<tr><td class="head" colspan="2">Opportunity #6</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>Valley Health - PKScribe</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Mick Majewski</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>5. Negotiate/Contract Sent</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Commit</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$1,200,000</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>9/30/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#28a745;">97</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>Valley Health - PKScribe is in Negotiation with a committed forecast and a substantial 1.2M ACV, signaling high confidence in deal progression. The close date of 9/30/25 adds urgency to finalize terms and signatures before quarter end. The KF score of 97 indicates very low risk and strong alignment, but the absence of notes leaves some execution details unresolved. The lack of bluesheet data does not reveal any red flags, yet a last mile contract review and procurement approval could still impact timing. The team should focus on locking the contract terms quickly and preparing a seamless handoff to delivery to safeguard the committed forecast.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Contract execution risk due to nearing quarter-end and procurement approvals</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Lock terms quickly, engage legal to draft and circulate final contract for signature, and align procurement to meet the target signature date.</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>(Proposed) Align legal to draft final contract and circulate for signature</li><li>(Proposed) Confirm kickoff and deployment plan with customer</li></ul></td>
</tr>
</table>

<table id="opp-6">
<tr><td class="head" colspan="2">Opportunity #7</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>Baystate - PK Autonomous Coding co-dev</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Amy Sullivan</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>4. Proposal/Price Quote</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Best Case</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$1,000,000</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>10/31/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#ffc107;">70</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>Baystate - PK Autonomous Coding co-dev is in the Proposal/Price Quote stage with a Best Case forecast and a potential value of $1,000,000. There is no available summary or notes indicating customer alignment or internal readiness, and there is no Bluesheet data to assess urgency or strategic fit. The KF score of 70 suggests healthy interest, but the absence of explicit next steps or scoping details introduces risk around finalizing requirements and pricing. To move forward, establish a concrete scoping agenda, define success criteria for the co-dev effort, and secure alignment on ownership and milestones. A clear path to closure will depend on finalizing scope, milestones, and pricing in a timely manner.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Lack of documented scope and pricing alignment increases risk of miscommunication with the customer.</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Schedule a scoping session to finalize requirements and pricing; produce a formal proposal with clear milestones and owners.</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>Schedule scoping call with customer to finalize requirements</li><li>Prepare and share final proposal and pricing (Proposed)</li><li>Confirm internal approvals and milestones (Proposed)</li></ul></td>
</tr>
</table>

<table id="opp-7">
<tr><td class="head" colspan="2">Opportunity #8</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>OBHG RCM replacement</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Amy Sullivan</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>1. Qualifying</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$1,000,000</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>8/21/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#ffc107;">70</span></td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Early stage with no forecast; risk of stall</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Agree on an initial forecast, identify decision milestones, and surface any red flags or blockers; ensure manager notes or bluesheet inputs are captured to clarify risk.</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>(Proposed) Define initial forecast and schedule a discovery call to validate decision criteria.</li><li>(Proposed) Capture any red flags or blockers in Bluesheet/Manager Notes.</li></ul></td>
</tr>
</table>

<table id="opp-8">
<tr><td class="head" colspan="2">Opportunity #9</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>USC Keck Autonomous Coding</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Amy Sullivan</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>3. Scoping</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Omitted</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$1,000,000</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>9/30/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#ffc107;">78</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>USC Keck Autonomous Coding sits in the Scoping phase with an omitted forecast and a high value engagement of $1M, suggesting significant potential but uncertain timing. The lack of an explicit forecast increases the risk of misalignment across stakeholders and potential delays in decision-making. The KF score of 78 places this deal in a higher risk category, underscoring the need for rapid capture of requirements and sponsor alignment. There are no manager notes or bluesheet context to sharpen the view, so proactive governance will be essential to avoid slipping the close date. Establishing a concrete forecast, a stakeholder map, and an execution plan will be critical to realize the revenue before the 9/30/25 deadline.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Lack of forecast clarity and multi-stakeholder alignment risk</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Create a forecast with a sponsor map, define scope and milestones, and schedule a steering committee to obtain an explicit forecast; confirm decision rights and deadlines.</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>(Proposed) Schedule scoping workshop and define success criteria</li><li>(Proposed) Confirm timeline with sponsor</li></ul></td>
</tr>
</table>

<table id="opp-9">
<tr><td class="head" colspan="2">Opportunity #10</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>SUNY Upstate Medical University - Strongline - Duress - New Business</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Joe Monaco</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>4. Proposal/Price Quote</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Omitted</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$850,000</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>10/31/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#dc3545;">51</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>SUNY Upstate Medical University is in the Proposal/Price Quote stage with an Omitted forecast and a substantial opportunity of $850,000. The summary notes show active evaluation of SL and Vocera with Joe preparing the proposal, indicating momentum but with forecast ambiguity. The absence of manager notes and bluesheet data reduces forecast clarity; a signed proposal will help lock in commitments and move the deal forward. With a close date at the end of October, timely action is required to convert the Best Case into a solid forecast. The risk is forecast omission and dependency on proposal quality to drive closure.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Forecast omitted; lack of forecast to guide revenue planning</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Clarify forecast status and secure defined close plan; verify decision-maker and dependencies.</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>Follow up to confirm forecast and timing on proposal. (Proposed)</li><li>Finalize pricing and send proposal. (Proposed)</li></ul></td>
</tr>
</table>

<table id="opp-10">
<tr><td class="head" colspan="2">Opportunity #11</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>HCA Home Health &amp; Hospice - Scribe - Existing Business</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Eric Valentin</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>3. Scoping</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Best Case</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$750,000</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>10/31/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#28a745;">87</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>HCA Home Health &amp; Hospice - Scribe is in Scoping with Best Case forecast and an existing business expansion implied by the $750,000 ACV. The KF score of 87 indicates a high probability of closing with solid momentum, though discovery is still needed to lock in scope, timeline, and success criteria. Manager notes are not present, and Bluesheet data is sparse, which reduces confidence in fully understanding the current position and decision drivers. To convert toward a win, ensure alignment on integration needs, clinical workflow impact, and procurement timing. A clear path to pricing and implementation milestones will help solidify the forecast.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">High reliance on uncertain scope and missing Bluesheet context increases execution risk.</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Engage sponsor in a targeted discovery to finalize scope and success metrics; populate Bluesheet fields with position, business impact, and decision criteria.</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>Confirm scope and decision criteria with sponsor (Proposed)</li><li>Populate Bluesheet with current position and expected benefits (Proposed)</li></ul></td>
</tr>
</table>

<table id="opp-11">
<tr><td class="head" colspan="2">Opportunity #12</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>St. Bernards- Scribe/Agents</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>David Swanson</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>4. Proposal/Price Quote</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Best Case</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$750,000</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>10/28/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#dc3545;">40</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>St. Bernards is currently in the Proposal/Price Quote stage with a Best Case forecast and a substantial potential of 750k. The KF score of 40 suggests a moderate likelihood of win without additional leverage or differentiating factors. There are no manager notes or bluesheet data to sharpen the forecast, and no explicit next steps documented. With a late-October close target, finalizing the price quote and obtaining customer buy-in will be critical to move toward a committed deal. A more defined path to closure, including decision-maker alignment and leverage points, will improve forecast reliability.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Reliance on Best Case forecast without confirmed decision-maker or committed terms</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Lock in a formal pricing/terms letter and obtain explicit customer approval or LOI.</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>Finalize and send formal price quote with terms. (Proposed)</li><li>Schedule customer decision-maker meeting to accelerate sign-off. (Proposed)</li></ul></td>
</tr>
</table>

<table id="opp-12">
<tr><td class="head" colspan="2">Opportunity #13</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>CUC - Platform Sale</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Eric Valentin</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>3. Scoping</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$500,000</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>10/31/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#dc3545;">55</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>KF score 55 indicates a moderate fit with potential upside if scope and value are clarified. The opportunity sits in Scoping with an ACV of $500,000 and a close date of 10/31/25, suggesting a near-term qualification cycle. The data shows no Manager Notes, Bluesheet data, or next steps, introducing risk around stakeholder alignment, technical fit, and procurement timing. Without explicit blockers or red flags, the primary risk is insufficient clarity on scope and success criteria. Action should be to finalize scoping, capture decision-makers, and document a concrete plan to advance.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Ambiguity in scope and stakeholder alignment</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Document a concrete scoping plan and identify the key decision-maker and technical owner to move forward</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>Schedule a scoping review with the customer and internal owners (Proposed)</li><li>Capture required requirements and a formalized timeline to progress (Proposed)</li></ul></td>
</tr>
</table>

<table id="opp-13">
<tr><td class="head" colspan="2">Opportunity #14</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>Doctors RCM</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>David Swanson</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>3. Scoping</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Best Case</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$500,000</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>10/31/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#dc3545;">49</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>KF score 49 reflects an average fit; Best Case forecast suggests potential upside if discovery confirms alignment. The opportunity is in Scoping with an ACV of $500,000 and a close date of 10/31/25, indicating a near-term push to define requirements. The data shows no Manager Notes, Bluesheet data, or explicit next steps, increasing the risk of blockers around stakeholders and procurement timing. Given the date proximity, it is essential to accelerate discovery, confirm decision rights, and document red flags if present. Action: build a detailed scoping plan, map stakeholders, and secure commitment to move to the next stage.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Ambiguity in next steps and stakeholder alignment</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Capture explicit next steps and confirm decision rights with key stakeholders to move forward</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>Accelerate discovery and identify decision rights (Proposed)</li><li>Document a formal scoping plan and next milestones (Proposed)</li></ul></td>
</tr>
</table>

<table id="opp-14">
<tr><td class="head" colspan="2">Opportunity #15</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>UHS - Referral</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>David Swanson</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>3. Scoping</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Best Case</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$500,000</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>10/29/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#ffc107;">62</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>UHS - Referral is in the Scoping stage with a solid potential of $500,000 and a Best Case forecast. The opportunity currently lacks formal guidance given the absence of manager notes or bluesheet data, which creates some ambiguity in progression. The KF score of 62 indicates moderate risk and the need for disciplined scoping to prevent misalignment. Without a documented scope, there is a risk of scope creep if requirements are not captured early. Establishing a clearly defined scope, acceptance criteria, and a realistic timeline will be key to converting to a committed revenue by the close date.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Unclear scope and requirements leading to scope creep</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Capture a formal scope document (SOW) with acceptance criteria; schedule a scoping workshop with the customer; lock down requirements and timelines.</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>(Proposed) Schedule scoping workshop with customer and finalize requirements</li><li>(Proposed) Align internal teams for delivery plan</li></ul></td>
</tr>
</table>

<table id="opp-15">
<tr><td class="head" colspan="2">Opportunity #16</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>Sutter-Caring Contacts</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>David Swanson</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>5. Negotiate/Contract Sent</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Best Case</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$345,000</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>10/29/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#dc3545;">57</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>Sutter-Caring Contacts is in the 5. Negotiate/Contract Sent stage with a Best Case forecast and an achievable ACV of $345,000. The deal appears near close, but final contract terms and signature remain the gating factor for conversion. The KF score of 57 indicates moderate risk and some uncertainty around closing readiness. There are no manager notes or bluesheet context to sharpen the forecast, so timely execution will depend on contract finalization and internal alignment. Securing a signed contract by the stated close date will be critical to realizing the Best Case forecast.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Contract approval/signature delays due to finalizing terms</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Secure a signed contract by establishing a clear signature plan with the customer and expediting legal review; schedule a contract review call and set a firm internal deadline.</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>(Proposed) Confirm contract terms with customer and set a firm signature date</li><li>(Proposed) Engage Legal to clear any redlines within 3 business days</li></ul></td>
</tr>
</table>

<table id="opp-16">
<tr><td class="head" colspan="2">Opportunity #17</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>Optum Wellmed new instance of PK</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Amy Sullivan</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>7. Final Contract Execution</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Commit</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$318,000</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>9/30/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#ffc107;">65</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td> Optum Wellmed new instance of PK is in 7. Final Contract Execution stage with a Commit forecast and an ACV of $318,000, close date 9/30/25. There are no manager notes or Bluesheet details available to illuminate contract risks or operational constraints. Although the deal is in late-stage execution, there is no additional risk data in the record. To safeguard the close, ensure final terms, approvals, and signatures are aligned and monitor for any contracting blockers. The primary risk is execution risk if signatures slip.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Lack of explicit risk data; execution risk if signatures slip</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Lock in final terms and secure approvals; maintain close coordination with procurement to avoid signature delays.</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>(Proposed) Confirm final contract terms and secure signatures; align with procurement timeline.</li><li>(Proposed) Validate no outstanding blockers in Manager Notes or Bluesheet.</li></ul></td>
</tr>
</table>

<table id="opp-17">
<tr><td class="head" colspan="2">Opportunity #18</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>Chapters- Intake</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Marc DeLaurentis</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>5. Negotiate/Contract Sent</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Best Case</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$260,000</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>10/31/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#ffc107;">66</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>Chapters- Intake is in 5. Negotiate/Contract Sent with an ACV of $260,000 and a close date of 10/31/25. There is currently no Manager Notes or Bluesheet data to guide risk assessment. The sizable potential revenue implies a meaningful deal, but terms negotiation and procurement alignment could pose hurdles. The KF score of 66 indicates solid opportunity with good likelihood of close. Active negotiation suggests a focused path to close, assuming terms can be agreed.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Contract negotiation risk; terms could impact price or scope</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Prepare a formal negotiation playbook and confirm acceptance of key terms with customer; lock-in milestones</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>Negotiate and finalize contract terms to move into signature</li><li>(Proposed) Schedule a contract review with legal</li><li>(Proposed) Confirm customer stakeholders and procurement sign-off</li></ul></td>
</tr>
</table>

<table id="opp-18">
<tr><td class="head" colspan="2">Opportunity #19</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>LHS-RCM</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>David Swanson</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>1. Qualifying</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$250,000</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>9/30/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#dc3545;">42</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>Low-stage opportunity (Qualifying) with a target of $250,000 and a close date of 9/30/25. The lack of a forecast status and missing notes indicates limited visibility into deal progression. There are no red flags or bluesheet data captured, suggesting the risk signals are not yet documented. The primary risk is deal stall due to early-stage qualification and undefined next steps, which could lead to no progress before the quarter ends. To improve momentum, establish a clear discovery plan, identify the main economic buyers, and lock in next-step actions and owner.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Early-stage status and lack of forecast/next steps create risk of deal stall.</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Define a structured discovery plan, assign an owner, and generate a forecast and concrete next steps to move the deal forward.</span></td>
</tr>
</table>

<table id="opp-19">
<tr><td class="head" colspan="2">Opportunity #20</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>Doctors Scribe</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>David Swanson</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>3. Scoping</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Best Case</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$200,000</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>10/31/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#dc3545;">57</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>Doctors Scribe is in Scoping with Best Case forecast and a $200,000 ACV, with a target close date of 10/31/2025. The KF score of 57 indicates a moderate win probability, suggesting progress in discovery but with room to accelerate. There is currently no manager forecast notes or Bluesheet data to corroborate buyer priorities or potential obstacles. The lack of documented description, current position, or red flags reduces confidence in the forecast and highlights a need for targeted discovery to validate the business case. Alignment on clinical workflow impact and an explicit next-step plan will be critical to convert this opportunity toward a favorable outcome.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Ambiguity in buyer priorities and lack of Bluesheet data create execution risk.</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Schedule a focused discovery conversation with the sponsor to confirm business need and decision criteria; populate Bluesheet fields with current position and business impact.</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>Schedule discovery call with sponsor (Proposed)</li><li>Populate Bluesheet with current position and business impact (Proposed)</li></ul></td>
</tr>
</table>

<table id="opp-20">
<tr><td class="head" colspan="2">Opportunity #21</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>Baxter Regional Medical Center - Strongline - New Business</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Timothy Knoll</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>3. Scoping</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Omitted</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$134,200</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>10/1/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#dc3545;">14</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>Baxter Regional Medical Center is in Scoping with an Omitted forecast and a potential value of $134,200. The only available notes indicate that scoping requests have not been responded to since 3/27, but a 2/13 call with the CNO (Rachel) shows interest in covering 2,200 staff and a request for a proposal. The plan mentions Lomax pulling together numbers and scheduling a WP safety committee meeting, highlighting a dependency on internal follow-up to move forward. There is limited manager or bluesheet context, which reduces visibility into customer priorities or readiness to approve scope. The KF score of 14 signals early-stage activity and the opportunity will require disciplined outreach and a concrete scoping plan to prevent further delays.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Customer responsiveness and dependency on internal follow-ups threaten timing for scoping and proposal delivery.</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Schedule a scoping call with the customerâ€™s leadership to finalize requirements and deliver a formal scoping proposal; confirm WP safety committee meeting date and attendees.</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>Schedule scoping call with customer to finalize requirements</li><li>Deliver formal scoping proposal and timeline (Proposed)</li><li>Confirm WP safety committee meeting date and attendees (Proposed)</li></ul></td>
</tr>
</table>

<table id="opp-21">
<tr><td class="head" colspan="2">Opportunity #22</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>SUNY expansion practices</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Amy Sullivan</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>5. Negotiate/Contract Sent</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Best Case</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$117,656</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>10/31/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#ffc107;">68</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>SUNY expansion practices is in Negotiate/Contract Sent with a Best Case forecast and a contract value around $117,656. With no manager notes or bluesheet data, forecast accuracy relies on the ongoing negotiation and client readiness to finalize terms. The close date at the end of October leaves a modest runway to finalize negotiations, but risk remains if terms require additional internal or procurement approvals. The KF score of 68 indicates a reasonable probability, but the absence of additional notes reduces confidence in forecast. To improve the odds, drive a concrete contract close plan and obtain explicit commitments from stakeholders.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Negotiation risk and terms finalization</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Set deadline for contract back-and-forth; obtain commitment from procurement.</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>Deliver final contract with agreed terms and secure internal approvals. (Proposed)</li><li>Obtain customer sign-off by 10/31/25. (Proposed)</li></ul></td>
</tr>
</table>

<table id="opp-22">
<tr><td class="head" colspan="2">Opportunity #23</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>CA DSH - Athelas Home Hardware &amp; Service - New Business</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Eric Valentin</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>7. Final Contract Execution</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Commit</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$93,123</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>9/25/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#ffc107;">69</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>CA DSH - Athelas Home Hardware &amp; Service is at Final Contract Execution with a Commit forecast and an actual ACV of $93,123. There is currently no Manager Forecast Notes or Bluesheet data available to provide additional context. Close date is 9/25/2025, signaling imminent finalization, but the risk of last-mile contract terms remains. With a KF score of 69, the deal shows healthy momentum, though execution risk persists. Overall, success will depend on timely contract closure and unblocking any procurement or legal hurdles.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Final contract close risk due to procurement/legal terms or sign-off delays</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Pre-close readiness package; confirm final terms and obtain required approvals; schedule a last-step review with legal and procurement</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>Validate final contract terms and obtain signatures by target date</li><li>(Proposed) Conduct a final pricing/discount review with procurement</li><li>(Proposed) Schedule a contract kick-off with customer and legal</li></ul></td>
</tr>
</table>

<table id="opp-23">
<tr><td class="head" colspan="2">Opportunity #24</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>Portneuf Medical Center - Strongline - Duress - New Business</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Timothy Knoll</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>7. Final Contract Execution</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Commit</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$76,425</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>9/30/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#ffc107;">62</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>6.23.25 - VOC. Adding outdoor. IT review ongoing. contract will not be reviewed until IT review completed.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">IT review ongoing delaying contract review</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Prioritize IT review completion and secure timely internal approvals to prevent last-minute delays.</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>(Proposed) Finalize IT review and obtain formal contract approvals.</li><li>(Proposed) Update Bluesheet/Manager Notes with IT dependencies and risk factors.</li></ul></td>
</tr>
</table>

<table id="opp-24">
<tr><td class="head" colspan="2">Opportunity #25</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>HCA UK - Integrations Project</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Eric Valentin</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>5. Negotiate/Contract Sent</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Best Case</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$69,200</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>10/31/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#ffc107;">73</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>HCA UK - Integrations Project is in Negotiate/Contract Sent with Best Case forecast and a $69,200 ACV. The KF score of 73 suggests a strong probability with ongoing negotation and favorable momentum. However, there is limited manager forecast data and Bluesheet context to confirm concrete timelines or procurement constraints. The deal would benefit from rapid alignment on contract terms, integration requirements, and expected go-live. Strengthening the commercial package and ensuring decision-maker alignment will be critical to close this quarter.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Limited forecast data and Bluesheet context create uncertainty in contract timing and decision authority.</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Synchronize with legal and procurement to align contract terms; populate Bluesheet with current position and decision makers.</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>Finalize contract terms and approvals (Proposed)</li><li>Populate Bluesheet with current position and decision makers (Proposed)</li></ul></td>
</tr>
</table>

<table id="opp-25">
<tr><td class="head" colspan="2">Opportunity #26</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>Shore Medical Center - Strongline - New Business</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Joe Monaco</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>4. Proposal/Price Quote</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Best Case</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$65,000</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>10/31/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#dc3545;">24</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td> Shore Medical Center opportunity is in Proposal/Price Quote stage with an ACV of $65,000 and a Best Case forecast. There are no manager notes or Bluesheet details available to illuminate constraints or risks. No red flags are documented in the data. The limited data creates ambiguity around next steps and likelihood of progressing through the sales process. Close attention to decision milestones and procurement requirements will help avoid stalls and improve the chance of moving toward a favorable outcome.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">No explicit risks documented; early-stage with potential for stall</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Capture initial next steps and establish clear decision milestones; solicit Manager Notes or Bluesheet inputs to surface any risks.</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>(Proposed) Push to final quote and obtain customer sign-off; confirm procurement schedule.</li><li>(Proposed) Capture any blockers in Bluesheet or Manager Notes.</li></ul></td>
</tr>
</table>

<table id="opp-26">
<tr><td class="head" colspan="2">Opportunity #27</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>Beth Israel Bayridge - Duress - Expansion</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Joe Monaco</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>7. Final Contract Execution</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$20,000</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>10/31/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#dc3545;">40</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>Beth Israel Bayridge is an expansion opportunity at the Final Contract Execution stage with a $20,000 ACV. There are no manager notes or bluesheet data documented, limiting visibility into closing dynamics or procurement timelines. Given the small size and lack of forecast, the primary risk is potential delays in contract execution due to procurement or legal review. The KF score of 40 suggests moderate momentum, requiring disciplined closing actions and clear contract terms. The path forward is to finalize the contract, secure approvals, and drive signature with a focused closing plan.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Contract execution and procurement delays may impede signature.</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Prepare contract for signature, obtain necessary approvals, and schedule a final contract review with the customer to accelerate close.</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>Finalize contract terms and obtain internal approvals</li><li>Schedule final contract review with customer and procurement (Proposed)</li><li>Obtain signature and close (Proposed)</li></ul></td>
</tr>
</table>

<table id="opp-27">
<tr><td class="head" colspan="2">Opportunity #28</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>Beth Israel Anna Jaques - Strongline - Expansion</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Joe Monaco</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>7. Final Contract Execution</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Best Case</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$16,000</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>10/31/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#ffc107;">66</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>Beth Israel Anna Jaques is at Final Contract Execution with a Best Case forecast and a $16,000 expansion opportunity. There are no manager notes or bluesheet data documented, providing limited visibility into the closing dynamics or procurement timing. At this stage, the primary risk is tied to contractual and procurement processes that could delay signature. The KF score of 66 indicates solid momentum, but timely legal reviews and internal approvals are required to push to closure. The path to close relies on a formalized contract review and timely execution by all parties.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Final contract and procurement delays may slow or block signature.</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Finalize contract terms and obtain internal approvals; schedule a final contract review with the customer and procurement to drive signature.</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>Finalize contract terms and obtain internal approvals</li><li>Schedule final contract review with customer and procurement (Proposed)</li><li>Obtain signature and close (Proposed)</li></ul></td>
</tr>
</table>

<table id="opp-28">
<tr><td class="head" colspan="2">Opportunity #29</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>Boston Childrens - Strongline Asset Tracking</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Joe Monaco</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>4. Proposal/Price Quote</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Best Case</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$0</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>10/1/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#dc3545;">57</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>Boston Childrens - Strongline Asset Tracking is in the 4. Proposal/Price Quote stage with a Best Case forecast and an active pilot. The 2/13-350 tag pilot is underway, and pricing has been sent for 5,000 tags, signaling intent to scale. There are no Manager Forecast Notes or Bluesheet entries providing additional context. This combination of pilot progress and pricing signals suggests upside, but conversion to full-scale deployment hinges on demonstrated ROI and operational alignment. The KF score of 57 indicates meaningful opportunity but with high variance until pilot results are solidified.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Pilot-to-scale conversion risk due to ROI uncertainty</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Define and agree on exit criteria for the pilot, a go/no-go decision, and a pricing/scale plan for a 5,000-tag deployment</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>Finalize pilot-to-scale criteria and schedule a formal review of results</li><li>(Proposed) Align pricing for 5,000 tags and set a deployment timeline</li><li>(Proposed) Confirm executive sponsorship and align on success metrics for scale</li></ul></td>
</tr>
</table>

<table id="opp-29">
<tr><td class="head" colspan="2">Opportunity #30</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>CAO + Medvanta RCM + Enterprise Bundle</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Adam Graves</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>4. Proposal/Price Quote</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Best Case</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$0</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>10/31/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#ffc107;">67</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>CAO + Medvanta RCM + Enterprise Bundle is in the 4. Proposal/Price Quote stage with a Best Case forecast. There is currently no Manager Forecast Notes or Bluesheet data to illuminate potential risks or deal drivers. The absence of ACV and detailed context suggests the opportunity is early-stage, requiring scoping and alignment across multiple product lines. The KF score of 67 indicates moderate opportunity potential. If we can secure scope and pricing for an enterprise bundle, the strategic value could be high.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Scope and integration risk across enterprise bundle; potential complexity and long sales cycle</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Define clear scope and integration requirements; secure executive sponsor; establish milestone-based deal plan</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>Define scope and timelines for the enterprise bundle</li><li>(Proposed) Align on pricing for the bundle</li><li>(Proposed) Schedule a joint solution design session with stakeholders</li></ul></td>
</tr>
</table>

<table id="opp-30">
<tr><td class="head" colspan="2">Opportunity #31</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>Chesapeake Regional MC - Pilot conversion</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Marc DeLaurentis</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>6. Contract Red-Line Received</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Commit</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$0</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>10/3/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#28a745;">82</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>Chesapeake Regional MC - Pilot conversion is in Contract Red-Line Received with a Commit forecast. There is no current ACV documented and there is no Manager Notes or Bluesheet data to illuminate additional deal context. The KF score is high at 82, signaling strong opportunity potential as the pilot moves toward deployment. Successful conversion will depend on timely redline closure and a clearly defined deployment plan.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Finalizing contract terms and achieving deployment-ready scope</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Accelerate redline closure, clarify deployment milestones, and align on success metrics to accelerate scale</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>Finalize redline and obtain sign-off</li><li>(Proposed) Schedule deployment plan and customer kickoff</li><li>(Proposed) Align on measurement criteria to accelerate scale</li></ul></td>
</tr>
</table>

<table id="opp-31">
<tr><td class="head" colspan="2">Opportunity #32</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>Firelands Regional Med Center - Ambient ENT</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Jason Absten</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>4. Proposal/Price Quote</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$0</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>10/31/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#dc3545;">44</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>Firelands Regional Med Center - Ambient ENT is in Proposal/Price Quote with no forecast status and no current ACV. The KF score of 44 suggests a moderate likelihood of closing, but the absence of documented manager notes or Bluesheet context leaves critical questions about buyer priorities and project scope. With no described business impact or current position, the deal relies on discovery to uncover needs, constraints, and procurement timelines. There is a potential opportunity if we can quickly validate fit and secure a defined implementation path. Next steps should focus on rapid discovery and alignment on value realization.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Ambiguity in buyer needs and lack of Bluesheet data create execution risk.</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Schedule a quick discovery session to capture the business case, timelines, and success criteria; populate Bluesheet with decision makers and expected benefits.</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>Qualify and validate requirements with stakeholder (Proposed)</li><li>Prepare and share a tailored proposal outline (Proposed)</li></ul></td>
</tr>
</table>

<table id="opp-32">
<tr><td class="head" colspan="2">Opportunity #33</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>KPC Group (AKA KPC Healthcare) - Pilot Conversion</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Marc DeLaurentis</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>5. Negotiate/Contract Sent</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Best Case</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$0</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>10/30/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#dc3545;">49</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>Opportunity centers on a pilot conversion with potential downstream full deployment; current actual ACV is $0 and the forecast is Best Case with a close in 10/30/25. The stage is 'Negotiate/Contract Sent', but there is no signed agreement, so the conversion risk remains high. There are no manager notes or bluesheet data to reveal hidden blockers, and no red flags are recorded. The top risk is whether the pilot will convert to a paid contract, given the lack of committed ARR and the dependency on pilot outcomes. To mitigate, align success criteria for the pilot, secure executive endorsement for conversion, and define a clear contract path if pilot KPIs are met.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Pilot may not convert to a paid contract; no committed ARR and reliance on pilot outcomes.</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Define pilot success criteria, secure executive sponsorship for conversion, and establish a formal pilot-to-contract plan with milestones.</span></td>
</tr>
</table>

<table id="opp-33">
<tr><td class="head" colspan="2">Opportunity #34</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>SIU Med CC + Analytics</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Amy Sullivan</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>1. Qualifying</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$0</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>8/21/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#28a745;">82</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>The SIU Med CC + Analytics opportunity sits in Qualifying stage with no forecast or next steps documented, indicating early discovery. The KF score of 82 suggests strong fit or potential value based on Scorecard inputs, but limited visibility undermines forecast reliability. There is no manager forecast notes to sharpen projection, and no Blue Sheet data to validate the opportunity. The close date is 8/21/25, implying a relatively short runway if the cycle moves quickly; however, the lack of a confirmed next step could stall progress. Without a stated forecast or explicit next steps, the risk is that this opportunity remains undefined and may miss the fiscal period. Recommend capturing a concrete next-step plan and securing a preliminary forecast to convert this to a qualified opportunity.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Lack of forecast and defined next steps in Qualifying stage</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Capture formal forecast and define 1-2 concrete next steps with owner and timeline.</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>Schedule discovery call to define scope and timeline. (Proposed)</li><li>Obtain internal pricing/terms approval. (Proposed)</li></ul></td>
</tr>
</table>

<table id="opp-34">
<tr><td class="head" colspan="2">Opportunity #35</td></tr>

<tr>
<td class="th">Opportunity Name</td>
<td>South County Hospital - PK + Ambient</td>
</tr>
<tr>
<td class="th">Owner</td>
<td>Dane Axelgard</td>
</tr>
<tr>
<td class="th">Stage</td>
<td>6. Contract Red-Line Received</td>
</tr>
<tr>
<td class="th">Forecast Category</td>
<td>Best Case</td>
</tr>
<tr>
<td class="th">ACV</td>
<td><strong>$0</strong></td>
</tr>
<tr>
<td class="th">Close Date</td>
<td>9/30/25</td>
</tr>
<tr>
<td class="th">KF Score</td>
<td><span style="font-weight:bold;color:#ffc107;">75</span></td>
</tr>
<tr>
<td class="th">Summary</td>
<td>This opportunity is at Contract Red-Line stage with a Best Case forecast, signaling potential upside but risk due to ongoing terms negotiations. The absence of manager forecast notes or bluesheet data reduces visibility into the likelihood of acceptance and final pricing. The 0 ACV indicates value has not yet consolidated; the 9/30/25 close date provides a reasonable runway if terms are promptly resolved. A successful red-line negotiation could convert this to a sizable win, but delays or unresolved terms could erode the forecast. The key risk is dependency on contract alignment; driving a tight negotiation plan will be critical to protect the Best Case scenario.</td>
</tr>
<tr>
<td class="th">Top Risk</td>
<td><span style="color:#dc3545;font-weight:500;">Contract red-line review and negotiation risk delaying close</span></td>
</tr>
<tr>
<td class="th">Mitigation</td>
<td><span style="color:#28a745;font-weight:500;">Set target negotiation SLAs and assign dedicated executive sponsor to expedite redline.</span></td>
</tr>
<tr>
<td class="th">Next Steps</td>
<td><ul style="margin:0; padding-left:20px;"><li>Coordinate contract redline walkthrough with legal and customer. (Proposed)</li><li>Confirm signed LOA or terms by target close date. (Proposed)</li></ul></td>
</tr>
</table>
</body>
</html>
